

REVIEW

Open Access

Hypersomnia and depressive symptoms: methodological and clinical aspects

Yves Dauvilliers^{1,2*}, Régis Lopez^{1,2}, Maurice Ohayon³ and Sophie Bayard^{1,2}

Abstract

The associations between depressive symptoms and hypersomnia are complex and often bidirectional. Of the many disorders associated with excessive sleepiness in the general population, the most frequent are mental health disorders, particularly depression. However, most mood disorder studies addressing hypersomnia have assessed daytime sleepiness using a single response, neglecting critical and clinically relevant information about symptom severity, duration and nighttime sleep quality. Only a few studies have used objective tools such as polysomnography to directly measure both daytime and nighttime sleep propensity in depression with normal mean sleep latency and sleep duration. Hypersomnia in mood disorders, rather than a medical condition *per se*, is more a subjective sleep complaint than an objective finding. Mood symptoms have also been frequently reported in hypersomnia disorders of central origin, especially in narcolepsy. Hypocretin deficiency could be a contributing factor in this condition. Further interventional studies are needed to explore whether management of sleep complaints improves mood symptoms in hypersomnia disorders and, conversely, whether management of mood complaints improves sleep symptoms in mood disorders.

Keywords: Depression, Mood, Sleep, Hypersomnia, Excessive daytime sleepiness, Narcolepsy

Introduction

Excessive daytime sleepiness (EDS) is commonly assumed to result from disturbed or insufficient sleep. Various symptoms associated with EDS have been reported in the literature, indicating a multifactorial mechanism [1]. EDS is associated with many sleep disorders, such as insomnia, obstructive sleep apnea syndrome, circadian rhythm sleep disorders, and restless legs syndrome. In addition, it is a marker symptom in rare hypersomnias of central origin. However, the most frequent associations are mental health disorders and, particularly, depression [2].

A large cross-sectional study of independent risk factors associated with EDS in the general population found that current depression is a major factor, the result being unchanged after controlling for antidepressant use [3]. We recently reported a 19.5% prevalence of EDS in

adults in the US [1]. However, using an EDS frequency of at least three times per week for at least three months with normal nighttime sleep duration, the prevalence was 4.7% and 1.5% in the presence of associated daytime impairment. In that study, EDS was associated with insufficient sleep, several sleep disorders, and general organic diseases in addition to psychiatric conditions (including anxiety and depressive disorders) and hypnotic and antidepressant use [1]. We previously reported strong associations between EDS and bipolar-II disorder as well as major depressive disorder (MDD) with atypical symptom features in a general elderly population [4]. Moreover, severity of EDS occurrence increased the risk of subsequent depression in elderly patients at four-year follow-up [5].

Cross-sectional studies have also repeatedly noted frequent sleep disturbances in depression [6]. Both EDS and insomnia form part of the clinical algorithm used to diagnose depression [7] and were initially considered to be a consequence of the disorder due to disturbances in monoamine activity [8]. Recent studies have suggested that sleep disorders may precede depression [5] and that non-depressed subjects with a family history of depression

* Correspondence: ydauvilliers@yahoo.fr

¹Centre de référence national sur les maladies rares (narcolepsie, hypersomnie idiopathique, syndrome de Kleine-Levin), Service de Neurologie, Unité des troubles du sommeil, Hôpital Gui-de-Chauliac, 80 avenue Augustin Fliche, Montpellier cedex 5 34295, France

²INSERM U1061, Université Montpellier I, Hôpital la Colombière 39, avenue Charles Flahault BP 34493 -pav 42 Calixte Cavalier, Montpellier cedex 5 34093, France

Full list of author information is available at the end of the article

commonly have rapid eye movement (REM) sleep abnormalities [9]. The mechanisms by which EDS contributes to the development of depressive symptoms remain unclear. Physiological hypotheses have implicated genes associated with both the monoamine and circadian systems, related to stress-induced arousal responses and subsequent overactivity of the hypothalamic-pituitary-adrenal axis or, alternatively, mediated by increased activation of REM sleep mechanisms [10].

In this article, we describe hypersomnia assessment methods, define hypersomnia in mood disorders, and review studies that have examined mood disorder symptoms in hypersomnias of central origin.

Definition and assessment of hypersomnias

In the literature, hypersomnia refers to a specific sleep-disorder-related diagnosis, such as narcolepsy in the International Classification of Sleep Disorders (ICSD-2) [11], or an associated symptom in various diagnostic entities, such as MDD in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) [7]. In the latter condition, the predominant complaint is excessive sleepiness for at least one month (or less if recurrent), evidenced by either prolonged sleep episodes or daytime sleep episodes occurring almost daily.

Excessive daytime sleepiness

The terms 'hypersomnia,' 'excessive somnolence,' 'excessive sleepiness' and 'EDS' are often used interchangeably, and EDS tends to be considered a disease or disorder. However, EDS is a symptom of a sleep disorder or other disease but not a disease *per se* [12]. Another problem with EDS is its definition, which is based mainly on one or two questions in epidemiological investigations, making for large differences across studies. The frequency, severity and duration of EDS greatly affect its prevalence, which ranges from 4% to 30% [1,12]. For example, ICSD-2 defines EDS as 'an inability to remain fully alert or awake, or a propensity to nod or doze when sedentary, during the wakefulness portion of the sleep/wake cycle. This occurs daily or almost daily for at least three months [11].' In clinical practice, EDS assessment usually involves self-report questionnaires. The most widely used is the Epworth Sleepiness Scale: the patient is instructed to make a probability judgment about the expectation of 'dozing' in eight different circumstances (for example, sitting and reading), a score above 10 being pathological [13]. Other questionnaires involve a momentary assessment of sleepiness, such as the Stanford Sleepiness Scale [14] and the Karolinska Sleepiness Scale [15].

Objective measures of EDS also exist. The Multiple Sleep Latency Test (MSLT) is the most commonly used [16]. The patient lies in bed in a darkened room in the

daytime and tries to fall asleep. The patient takes five 20-minute naps, each two hours apart. Mean sleep latency <8 minutes is pathological and <5 minutes is severe. However the EDS complaint rarely correlates with objective findings on the MSLT. An alternative to the MSLT is the Maintenance Wakefulness Test (MWT), which assesses the capacity to maintain wakefulness [17]. During two or four 20- or 40-minute sessions, the patient sits in bed and attempts to remain awake. The most sensitive four-trial 40-minute MWT protocol considers latency <19 minutes as abnormal [17,18]. In rare circumstances, prolonged 24-hour continuous sleep recording is required to assess the degree of sleepiness.

Excessive quantity of nocturnal sleep

Abnormally long nighttime sleep may be a major complaint in central hypersomnias (that is, idiopathic hypersomnia) and in the presence of associated conditions. Excessive sleep quantity varies across subjects and with age, younger individuals having longer nighttime sleep. The pathological cut-off of 9, 10, or 11 hours across the night and the 24-hour period remains controversial [19]. Based on a recent large cross-sectional telephone survey of adults in the US, we found that 6.3% of the sample reported a sleep duration of 9 hours or greater during the main sleep episode, and 8.4% reported sleeping at least 9 hours per 24-hour period [20]. In addition, 25.1% of subjects sleeping ≥ 9 hours per night and 40.1% of subjects sleeping ≥ 9 hours per 24-hour period also experienced excessive sleepiness. Moreover, excessive nighttime sleep is rarely an isolated symptom, as it frequently coexists with other organic, mental, and sleep disorders.

Because most studies report the total amount of nighttime sleep or sleep across a 24-hour period using only one or two questions, a sleep diary or actigraphy would be useful to validate the data. A sleep diary is a daily log used to record sleep-wake patterns over a period of weeks [21]. Extensively used in insomnia and circadian rhythm sleep disorders, the sleep diary allows quantifying extended nocturnal sleep and daytime naps along with available day-to-day and weekday-to-weekend variability symptoms. However, all these data are subjective, with frequent differences between the patient's perceived nighttime and daytime sleep and objective sleep recording, and a tendency to overestimate sleep over 24 hours. Much less expensive than polysomnography (PSG), wrist actigraphy is a promising clinical tool for measuring rest-activity patterns and estimates of sleep-wake patterns over multiple days and nights [22,23]. Actigraphy permits the documentation of extended nocturnal sleep and daytime naps in clinical hypersomnia populations, but again with a tendency to overestimate sleep instead of rest, and to underestimate wake during the day [24]. The standard objective measure of nocturnal sleep is expensive in-lab PSG. PSG

is typically performed during the major sleep period, often involving six to ten hours of recording, which prevents gathering information about extended nocturnal sleep or napping behavior. Prolonged and continuous 24-hour PSG under an *ad-libitum* protocol can objectively measure extended nocturnal sleep [25,26]. This procedure is rarely performed however, and only in a few sleep laboratories at high cost, in the absence of standardization or age- and gender-normative data. Nevertheless, without this procedure, it is difficult to distinguish whether hypersomnia consists of actual extended sleep or whether it simply represents an extra time spent in bed without necessarily sleeping, known as clinophilia.

Hypersomnia associated with mood disorders

Diagnostic criteria for hypersomnia associated with mood disorders are described in three classification systems: the DSM-IV-TR [7], the ICSD2 [11], and the International Classification of Diseases (ICD-10) [27]. A complaint of excessive sleep quantity or EDS is always required. The predominant complaint of excessive sleepiness, evidenced by either prolonged or daytime sleep episodes occurring almost daily, is mandatory for a hypersomnia diagnosis related to other mental disorders under the DSM-IV. A complaint of EDS or excessive sleep is required for the diagnosis of hypersomnia not due to substance abuse or known physiological condition (nonorganic hypersomnia) under the ICSD-2. Excessive daytime sleep or sleep attacks not accounted for by inadequate sleep and/or prolonged transition to the fully aroused state upon awakening (sleep drunkenness) are criteria for non-organic hypersomnia under the ICD-10.

The ICD-10 and DSM-IV-TR include a symptom duration criterion of at least one month, and both imply either distress or impairment in social and/or occupational areas. The ICSD-2 is the only system that recommends objective measurement with PSG. However, it does not stipulate the daytime or nocturnal sleep duration, assessment procedures, or pathological cut-offs. Reduced sleep efficiency, increased sleep frequency, and increased number of awakenings together with 'variable but often normal' mean sleep latency on the MSLT were only proposed.

The proposed DSM-5 criteria for sleep-wake disorders nosology planned for publication this year included major changes regarding hypersomnia with elimination of the diagnosis of 'primary hypersomnia' in favor of 'hypersomnia disorder,' with concurrent specification of clinically comorbid conditions [28]. These modifications will also lead to elimination of 'sleep disorder related to another mental disorder' and 'sleep disorder due to a general medical condition,' in favor of 'hypersomnia disorder' with concurrent specification of clinically comorbid medical and psychiatric conditions. Sleep disorders

per se are frequently accompanied by depression, anxiety and other cognitive mental status changes that warrant independent clinical attention and must be addressed in treatment management. As the primary users of DSM are mental health and general medical clinicians, not sleep disorder specialists, new DSM5 sleep-wake disorders criteria also included aggregation of hypersomnia disorder and narcolepsy without cataplexy, which will be distinguished from narcolepsy-cataplexy/hypocretin-1 deficiency disorder. Based on a recent cross-sectional telephone survey, a new definition of hypersomnia has been proposed in the upcoming DSM-5 revision including a frequency of 'excessive sleepiness' (defined by either recurrent periods of irrepressible need to sleep or to nap within the same day; recurrent naps within the same day; a nonrestorative/unrefreshing prolonged main sleep episode of nine hours or more; and/or confusional arousals-sleep drunkenness) at least three times per week for at least three months, despite normal main sleep duration lasting seven hours or longer, with significant daytime distress/impairment leading to a final prevalence of 1.5% [1].

Definition and assessment of mood disorders

Diagnostic criteria for MDD are based on the presence of either sad mood and/or anhedonia plus four out of nine additional symptoms, including insomnia or hypersomnia [7]. Atypical depression may be considered a distinct entity or else a phase of MDD that evolves over time when the disorder becomes more chronic. To be qualified as having atypical features, a depressed patient must experience significant mood reactivity plus at least two other features, also including hypersomnia [7]. Dysthymic disorder (DD) diagnosis requires low mood present almost daily for two years plus at least two other MDD symptoms, including hypersomnia [7]. Three bipolar-related diagnoses (BD) have been individualized: BD-I, BD-II, and cyclothymia. Sleep disturbances are listed as symptoms of each BD subtype, with reduced need for sleep for manic and hypomanic episode and insomnia or hypersomnia for depressive episode. The initial description of seasonal affective disorder (SAD) stipulated frequent occurrence of hypersomnia, dysphoria, hyperphagia, and weight gain [29]. Currently, SAD is not considered a separate disorder, but instead a 'course specifier' that may exist in MDD or BD [7]. Mood disorders are generally diagnostically assessed with the Structured Clinical Interview for DSM-IV Axis 1 Disorder [30]. This instrument is a semi-structured interview for making standardized, reliable, and accurate diagnoses of the DSM-IV Axis 1 disorders. Self- or hetero-report questionnaires are also commonly used to quantify mood symptom severity. Self-report questionnaires include the Beck Depression Inventory (BDI-II) [31], the Hamilton Depression Rating

Scale [32], the Montgomery Åsberg Rating Scale [33], the Zung Rating Scale for Depression [34], the Hospital Anxiety and Depression Scale [35], and the Inventory of Depressive Symptomatology (self-rating, IDS-SR₃₀) [36]. These instruments are completed by the patients themselves. Note that the IDS also has a clinician-rated version (IDS-C₃₀) [36].

However, these questionnaires should be interpreted with caution when assessing the presence and severity of depressive symptoms, higher scores being potentially without a diagnosis of mood disorder and vice versa. Similar scores using these questionnaires may also obscure important individual differences in the relative severity and frequency of somatic/affective versus cognitive symptomatology. Accordingly, we must emphasize that somatic and cognitive symptoms can be signs of physical illness and that self-report questionnaires often over-identify depression in clinical populations [37], such as patients with central hypersomnias.

Hypersomnia associated with mood disorders

Subjective assessment of hypersomnia

The hypersomnia symptoms associated with mood disorders are not specific and may include non-imperative EDS, long non-refreshing naps, long sleep time, and sleep inertia. EDS should be distinguished from insufficient sleep and fatigue. Fatigue is not necessarily relieved by increased sleep and may be unrelated to sleep quantity or quality. However, it is difficult to differentiate between EDS and fatigue, which may overlap considerably in mood disorders. It is also particularly difficult to differentially diagnose between idiopathic hypersomnia and less severe forms of depression (for example, dysthymia).

Albeit a diagnostic symptom for mood disorders, hypersomnia is largely understudied in this area. A recent review reported widely varying estimates of hypersomnia in MDD across age, gender and studies, ranging from 8.9% in childhood (<13 years) to 75.8% in young adulthood [2], with a higher prevalence in females. Few studies have explored the presence of hypersomnia symptoms in MDD with atypical features, with frequency varying from 24% to 56% [38,39]. The large frequency range likely reflects ambiguous definitions of hypersomnia, which vary between studies and are mostly based on a response to a single question [40-42]. The basis of hypersomnia in MDD is poorly understood; one may hypothesize that hypersomnia is related to abnormal sleep homeostasis in MDD. Interestingly, a recent high density electroencephalography study suggested that the presence of hypersomnia in MDD is associated with reduced parieto-occipital slow wave activity compared to those without hypersomnia [43].

Hypersomnia assessed with a single yes/no response (for example, 'sleeping too much') was found to be refractory after antidepressant intake, persisting even when

other symptoms had remitted [44,45]. Hypersomnia may also predict the onset of a major depressive episode [5,42], and hypersomnia persistence after depressive symptoms have been managed may be a condition in those at risk for developing recurrent depressive episodes [41,46].

In a cohort of consecutive BD-II and MDD outpatients, 'increased sleep' was reported by 37.6% and 24%, respectively [38]. Another study in BD exploring hypersomnia complaints that used several questionnaires and a sleep diary for seven days between episodes showed that hypersomnia may predict the risk of future depressive symptoms, with no interaction with baseline depressive symptoms or medication use [47]. Lifetime hypomanic episodes were also associated with persistent EDS in an elderly population [4]. The frequency of hypersomnia symptoms in SAD ranged from 67% to 76% across studies [2,48-52]. However, these studies used different diagnostic tools to assess sleep complaints. One study used an original methodological approach to explore hypersomnia complaints in patients with SAD: a standard interview guide, questionnaires, and sleep diaries [53]. Results indicated longer self-reported total hours of sleep in winter than in summer but with large differences between assessment methods, and again with a tendency to overestimate total sleep time using self-reports.

Objective assessment of hypersomnia

A few studies have used objective methods to investigate extended nocturnal sleep and EDS in mood disorders, but all reported no difference in mean sleep latency or sleep duration between patients with mood disorders and healthy controls. REM sleep was almost absent during daytime naps in the depressed phase of patients with BD [54]. Hypersomnia complaints were independent of the mean sleep latency and were related more to lack of interest and decreased energy due to depression in BD [54]. Another study revealed neither pathological sleep latencies on the MSLT nor abnormal total sleep time on prolonged PSG in patients with hypersomnia associated with mood disorders, that is, dysthymia, BD, and recurrent MDD [55]. Normal MSLT latency was also reported in dysthymic patients compared to patients with idiopathic hypersomnia and healthy controls [56]. Using the PSG and a non-conventional objective measure of EDS (that is, two 60-minute naps at 9:00 and 12:30), Vgontzas and co-workers have compared the nighttime and the objective sleepiness of drug-free patients with diagnosis of primary (idiopathic) versus psychiatric hypersomnia (that is, mood, somatoform, anxiety, and personality disorders) [57]. This group found that patients with psychiatric hypersomnia, although having complaints of EDS, showed both during the day and during the night lower sleep propensity (that is, higher sleep latency and total

wake time) than patients with idiopathic hypersomnia and controls [57].

Taken together, there is no objective evidence supporting the view that patients with mood disorder have either abnormal mean sleep latency on the MSLT or objective extended nocturnal sleep. However, these patients spent a substantial amount of time in bed, acknowledged as 'resting' more than 'sleeping' (called clinophilia), with major distress and impacts on the natural course of mood disorders.

One may question whether the diagnosis of hypersomnia requires objective evidence of daytime/nighttime sleepiness or hypersomnia may be resumed as a 'subjective sleep complaint.' The complaint of EDS is rarely corroborated by the MSLT results, particularly in the context of associated mood disorders. Paralleling PSG-MSLT studies of hypersomnia in mood disorders, PSG evidence for insomnia often does not match self-report, and yet insomnia is currently considered an independent disorder. We do believe that hypersomnia diagnosed by a structured clinical interview as in proposed DSM-5 criteria merits clinical attention [28]. Thus, hypersomnia associated with mood disturbances may be a clinically-defined condition with significant socio-economic burden [58] that may justify a treatment. To date, no pharmacological drugs have been approved to manage hypersomnia in depressive disorders. The management bias is a concern, with potential interactions between EDS, extended nocturnal sleep complaints and drug intake. Some basic recommendations can be proposed, such as avoiding psychotropic sedative drugs (that is, benzodiazepine) and giving priority to noradrenergic antidepressant treatments for their action on the wake drive. Treatment with antidepressants, such as selective serotonin reuptake inhibitors and reuptake inhibitors of serotonin and noradrenalin, rather than psychostimulants, may be considered for patients when a mood disorder cannot be definitely ruled out as the cause of hypersomnia. However, complaints of EDS and extended nocturnal sleep may persist as refractory symptoms, despite adequate medication or behavioral and cognitive therapy that improve other symptoms. Further assessments, including objective measures of EDS, may then be useful to formally exclude an underlying central hypersomnia disorder.

Mood symptoms associated with hypersomnia disorders

Comorbidity between hypersomnia disorders and mood symptoms, particularly depression, is frequently reported in both clinical and research settings. However, the causal relationship between the two conditions remains unclear. Hypersomnia symptoms may also be misdiagnosed as depression, because MDD symptoms according to the DSM-IV-TR are common features of hypersomnia disorders.

Narcolepsy with cataplexy

Narcolepsy is an orphan sleep disorder (0.026% of the general population) characterized by a clinical history of EDS and abnormal manifestations of dissociated REM sleep, such as cataplexy (that is, sudden loss of muscle tone triggered by strong emotions), hypnagogic hallucinations, and sleep paralysis [59]. Narcolepsy typically starts during adolescence, a critical period of normal development and interpersonal relationship building [60]. Cataplexy is the best clinical diagnostic marker for the disease, occurring in 70% to 80% of patients. Two separate entities are individualized: narcolepsy with and without cataplexy [11]. Narcolepsy diagnosis requires nocturnal PSG recording followed by the MSLT, the latter showing a mean sleep latency <8 minutes and two or more sleep onset REM periods (SOREMPs).

For 120 years after it was identified, narcolepsy was attributed to psychiatric etiologies [61]. In the 2000s, however, it was determined that when cataplexy is present, narcolepsy is almost always caused by an immune-mediated destruction of orexin/hypocretin neurons located in the lateral hypothalamus [62,63]. Accordingly, low-undetectable cerebrospinal hypocretin-1 is observed in almost all cases of narcolepsy with cataplexy, but in only 10% to 20% in narcolepsy without cataplexy [64-67]. Studies linking loss of hypocretin neurons to human narcolepsy have spurred interest in improving the disease phenotype. Neuroanatomical studies indicate that hypocretin projections are widespread, including the cortex, the basal forebrain, limbic structures (for example, amygdala, ventral tegmental area), the thalamus, most of the brainstem (that is, locus coeruleus, raphe nucleus, and cholinergic tegmental nuclei) and the spinal cord [68]. The hypocretins act primarily as excitatory neurotransmitters to control monoaminergic and cholinergic neuron activity. Hypocretin deficiency induces a cholinergic-monoaminergic imbalance, with primary effects on vigilance as well as other functions, including mood regulation. Because hypocretins are also involved in neuroendocrine functions and stress reactions through stimulation of the hypothalamus-pituitary-adrenal axis, hypocretin deficiency *per se* may trigger mood disturbances and psychological alterations through diverse pathways.

High levels of psychopathology were frequently reported in cross-sectional studies in narcolepsy, with a high prevalence of self-reported depressive symptoms [69-72]. In a lifetime approach case-control study using DSM-IV-TR criteria, increased psychotic symptoms were found in narcolepsy with cataplexy, with no increase in depression frequency [73]. However, psychotic-like symptoms were induced by amphetamine intake and not by the disease *per se*, and symptoms were resolved when the dose was lowered or treatment changed to modafinil [73]. Another case-control study found mood disorder symptoms in

one-third of narcolepsy patients. Nevertheless, no significant difference was found between patients and controls regarding the formal mood disorder diagnosis [74]. In contrast, more than half the patients had anxiety or panic attacks and 35% had an anxiety disorder [74]. Regarding depressive symptomatology, the frequency of moderate to severe symptoms ranged from 15% to 37% in narcolepsy [75-78]. Our large cross-sectional narcolepsy study found that depressive symptoms (using the BDI-II) were associated with greater EDS severity, greater alterations in physical and mental health quality of life, as well as the presence of REM sleep manifestations, such as cataplexy, hypnagogic hallucinations and sleep paralysis [76]. Although depressed patients generally tend to overscore on any scale, these data reinforced reported associations between depressive symptoms, hypnagogic hallucinations, and sleep paralysis in a population-based study [79]. A similar frequency of depressive symptoms was found in other narcoleptic populations and using other questionnaires [80-82]. Interestingly, in a five-year cohort study of patients with narcolepsy-cataplexy, mood symptoms remained relatively stable, with 25% of patients showing constant moderate to severe mood symptoms across assessments [81]. Globally, a high frequency of depressive symptoms has been systematically reported in narcolepsy with cataplexy, supporting the hypothesis of an endogenous depression [61,76,81]. This condition was previously suggested based on reduced nighttime REM sleep latency, increased REM sleep pressure and sleep fragmentation in both narcolepsy and major depression.

Although there is no cure for narcolepsy, psychostimulants such as modafinil, methylphenidate, amphetamine, and sodium oxybate are used to treat EDS and sleep attacks. Cataplexy is managed with sodium oxybate and antidepressant drugs [59]. Hence, most drugs used to manage cataplexy have mood-modifying properties. When assessing treatment effects on disease severity and psychological consequences, we observed that patients with narcolepsy with cataplexy treated with anticataplectics (mainly tricyclic agents and selective serotonin reuptake inhibitors) had more depressive symptoms and greater quality of life alterations compared to patients treated with stimulants alone [76]. Higher baseline severity of REM sleep manifestations would normally lead to higher prescriptions of anticataplectics. However, our study revealed that anticataplectics at doses prescribed for cataplexy management were ineffective in treating depressive symptoms [76].

Recent studies also support the role of specific hypocretin receptors in the modulation of depression-like behavior. A behavioral mice study after genetic or pharmacologic inhibition of hypocretin receptor signaling suggested that the hypocretin activity balance at either receptor 1 or receptor 2 produced an anti-depressant- or

pro-depressant-like effect depending on the subtype activated [83].

Outside of the narcolepsy scope, some human studies have compared the levels of hypocretin-1 in the cerebrospinal fluid (CSF) in patients with mood disorders with the levels in healthy controls leading to controversial results. A reduced amplitude in diurnal variations of hypocretin-1 has been found in patients with bipolar or unipolar depression [84]. Brundin and co-workers found that suicidal patients with major depressive disorder had significantly lower CSF hypocretin levels than other suicidal patients [85]. In contrast other studies found similar CSF hypocretin-1 levels in patients with MDD and controls [86,87]. In addition, CSF hypocretin-1 levels did not correlate with the severity of depressive episode, the symptoms of depression or the number of episodes [86,87]. To our best knowledge, no studies have reported whether CSF hypocretin-1 levels are altered in depressive patients with hypersomnia or not. However, some recent results hold promise for the use of non-selective hypocretin-1 and α -2 agonists and antagonists to treat several neuropsychiatric disorders, including narcolepsy, insomnia, and drug addiction. Nevertheless, potential unwanted side effects must be carefully monitored.

Idiopathic hypersomnia

The prevalence of idiopathic hypersomnia (IH) in the general population is unknown. The age of symptom onset varies, but is frequently between 10 and 30 years [88,89]. Its pathophysiology is almost totally unknown, with no clear biological or genetic markers. Two forms of IH have been individualized: IH with and without long sleep time (LST) [11]. IH with LST is characterized by three major symptoms: (1) constant daily excessive sleepiness with unwanted and prolonged (≥ 1 hour) naps, less irresistible than in narcolepsy, and unrefreshing irrespective of duration; (2) long nocturnal sleep, uninterrupted and prolonged, with ≥ 10 hours of sleep; and (3) difficulty awakening after nighttime or daytime sleep, with frequent problems reacting adequately to external stimuli upon awakening, called 'sleep drunkenness' or 'sleep inertia.' IH without LST is characterized by isolated EDS. Daytime sleep episodes may be more irresistible, shorter, and more refreshing than in IH with LST. Nocturnal sleep in IH without LST is normal, with rare sleep inertia. However, some patients share clinical symptoms of both forms of IH, with prolonged nocturnal sleep time without sleep inertia, and others with nocturnal sleep of normal duration but with major sleep drunkenness [25,88,89]. Other symptoms such as mood changes (but not major depression), headache, and manifestations of neurovegetative impairment may be reported. IH diagnosis is based on clinical features and PSG followed by the MSLT (for IH without LST) or 24-hour continuous PSG under an

ad libitum sleep/wake protocol (for IH with LST) to objectively confirm hypersomnia, ascertain the diagnosis and rule out other causes of hypersomnia (for example, insufficient sleep, sleep apnea syndrome, narcolepsy).

Depressive symptoms were noted in 15% to 25% using clinic-based samples of patients affected with IH, values being always higher than in the general population [55,56,76,90]. Mood changes not qualifying for a mood disorder diagnosis may precede or follow EDS onset and evolve independently. However, MDD (being an exclusion criterion) is incompatible with an IH diagnosis, unlike narcolepsy-cataplexy, which is potentially associated with mood disorders. Hence, it is unrealistic to estimate the frequency of mood disorders and depressive symptom severity in both forms of IH. However, we may suggest a bridge between hypersomnia associated with mood disorders or with depressive symptoms only and IH, with difficulty distinguishing the two conditions in some cases. Prospective studies are needed to unravel this issue, more specifically, to clarify whether mood changes in IH are consequent to difficulty adapting to the disease or whether they indicate a primary brain dysfunction.

Behaviorally induced insufficient sleep syndrome

Behaviorally induced insufficient sleep syndrome (BISS), or self-induced sleep restriction, is an individualized clinical entity in the ICSD-2 [11]. BISS requires three criteria: (1) EDS complaint lasting at least three months, (2) shorter than expected habitual main sleep episode and (3) extended sleep when the habitual sleep schedule is not maintained (weekends and holidays). No epidemiological study has investigated BISS prevalence in the general adult population. However, one study reported a 7.1% prevalence in outpatient clinic patients with a complaint of EDS [91]. From computerized self-report questionnaires, estimated BISS prevalence was 10.4% in a large Norwegian cohort of students and associated with severe self-reported depressed mood [92]. Interestingly, the presence of BISS was recently found to increase suicidal tendencies in Korean adolescents, even after controlling for BDI scores [93]. The limitations of these studies are the use of self-report measures and cross-sectional designs. Longitudinal approaches are needed to confirm the causal relationship between BISS and mood disorder development.

Conclusions

The associations between depression and daytime and nighttime sleepiness are complex and potentially bidirectional. The greatest challenges in the literature are the varying definitions of hypersomnia and the wide clinical heterogeneity of depression. Although objective tools such as PSG enable direct sleep measurement, they are

unrealistic for use in large-scale population-based studies. Given the different methods used, the conflicting results are unsurprising. Nevertheless, no objective hypersomnia has been recorded consequent to mood disorders. Conversely, mood symptoms are frequently reported in hypersomnia disorders of central origin. Further interventional studies are needed to explore whether the management of sleep complaints improves mood symptoms in hypersomnia disorders and whether the management of mood complaints improves sleep symptoms in mood disorders.

Abbreviations

BDHI: Beck Depression Inventory; BISS: behaviorally induced insufficient sleep syndrome; BP: bipolar disorder; BP-II: bipolar-II disorder; CSF: cerebrospinal fluid; DD: dysthymic disorder; DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision; EDS: excessive daytime sleepiness; HAM-D: Hamilton Depression Rating Scale; ICD-10: International Classification of Disease, 10th Edition; ICSD-II: International Classification of Sleep Disorders, 2nd Edition; IDS: Inventory of Depressive Symptomatology; IDS-SR₃₀: Inventory of Depressive Symptomatology (self-rating); IDS-C₃₀: Inventory of Depressive Symptomatology (clinician rating scale); IH: idiopathic hypersomnia; LST: long sleep time; MADRS-S: self-assessment version of the Montgomery Åsberg Rating Scale; MDD: major depression disorder; MSLT: Multiple Sleep Latency Test; MWT: Maintenance Wakefulness Test; PSG: polysomnography; REM: rapid eye movement; SAD: seasonal affective disorder; SOREMPs: sleep onset REM periods; SPAQ: season patterns assessment questionnaire; BISS: behaviorally induced insufficient sleep syndrome; ZRSD: Zung Rating Scale for Depression.

Competing interests

SB, RL and MO declare that they have no competing interests. YD has received speaker's honoraria and funding for travel to conferences from UCB Pharma, Cephalon, Novartis, Jazz, and Bioprojet. YD has participated on advisory boards of Jazz, UCB Pharma, and Bioprojet. This was not an industry-supported study.

Authors' contributions

YD and SB performed the literature search and wrote the first draft of the manuscript. RL and MO participated in writing the paper. All authors have read and approved the final manuscript.

Author details

¹Centre de référence national sur les maladies rares (narcolepsie, hypersomnie idiopathique, syndrome de Kleine-Levin), Service de Neurologie, Unité des troubles du sommeil, Hôpital Gui-de-Chauliac, 80 avenue Augustin Fliche, Montpellier cedex 5 34295, France. ²INSERM U1061, Université Montpellier I, Hôpital la Colombière 39, avenue Charles Flahault BP 34493 -pav 42 Calixte Cavalier, Montpellier cedex 5 34093, France. ³Stanford Sleep Epidemiology Research Center, Stanford University, School of Medicine, 3430 W. Bayshore Road, Palo Alto, CA 94303, USA.

Received: 19 November 2012 Accepted: 27 February 2013

Published: 21 March 2013

References

1. Ohayon MM, Dauvilliers Y, Reynolds CF: **Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology.** *Arch Gen Psychiatry* 2012, **69**:71–79.
2. Kaplan KA, Harvey AG: **Hypersomnia across mood disorders: a review and synthesis.** *Sleep Med Rev* 2009, **13**:275–285.
3. Bixler EO, Vgontzas AN, Lin HM, Calhoun SL, Vela-Bueno A, Kales A: **Excessive daytime sleepiness in a general population sample: the role of sleep apnea, age, obesity, diabetes, and depression.** *J Clin Endocrinol Metab* 2005, **90**:4510–4515.

4. Tsuno N, Jaussent I, Dauvilliers Y, Touchon J, Ritchie K, Besset A: **Determinants of excessive daytime sleepiness in a French community-dwelling elderly population.** *J Sleep Res* 2007, **16**:364–371.
5. Jaussent I, Bouyer J, Ancelin ML, Akbaraly T, Pérès K, Ritchie K, Besset A, Dauvilliers Y: **Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly.** *Sleep* 2011, **34**:1103–1110.
6. Manber R, Haynes T, Siebern AT: **Sleep and Psychiatry Disorders.** In *The Oxford Handbook of Sleep and Sleep Disorders*. 1st edition. Edited by Morin CM, Espie CA. Oxford University Press; 2012:471–501.
7. American Psychiatric Association: *Diagnostic and Statistical Manual for Mental Disorders*. 4th edition. Washington, DC: American Psychiatric Association; 1994.
8. Staner L: **Comorbidity of insomnia and depression.** *Sleep Med Rev* 2010, **14**:35–46.
9. Rao U, Hammen CL, Poland RE: **Risk markers for depression in adolescents: sleep and HPA measures.** *Neuropsychopharmacology* 2009, **34**:1936–1945.
10. Monteleone P, Maj M: **The circadian basis of mood disorders: recent developments and treatment implications.** *Eur Neuropsychopharmacol* 2008, **18**:701–711.
11. American Academy of Sleep Medicine: *International Classification of Sleep Disorders, 2nd edition: diagnostic and coding manual*. Westchester, IL: American Academy of Sleep Medicine; 2005.
12. Ohayon MM: **From wakefulness to excessive sleepiness: what we know and still need to know.** *Sleep Med Rev* 2008, **12**:129–141.
13. Johns MW: **A new method for measuring daytime sleepiness: the Epworth sleepiness scale.** *Sleep* 1991, **14**:540–545.
14. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC: **Quantification of sleepiness: a new approach.** *Psychophysiology* 1973, **10**:431–436.
15. Akerstedt T, Gillberg M: **Subjective and objective sleepiness in the active individual.** *Int J Neurosci* 1990, **52**:29–37.
16. Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, Lee-Chiong T, Hirshkowitz M, Daniel LL, Bailey D, Berry RB, Kapen S, Kramer M, Standards of Practice Committee of the American Academy of Sleep Medicine: **Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test.** *Sleep* 2005, **28**:113–121.
17. Arand D, Bonnet M, Hurwitz T, Mitler M, Rosa R, Sangal RB: **The clinical use of the MSLT and MWT.** *Sleep* 2005, **28**:123–144.
18. Doghramji K, Mitler MM, Sangal RB, Shapiro C, Taylor S, Walsleben J, Belisle C, Erman MK, Hayduk R, Hosn R, O'Malley EB, Sangal JM, Schutte SL, Youakim JM: **A normative study of the maintenance of wakefulness test (MWT).** *Electroencephalogr Clin Neurophysiol* 1997, **103**:554–562.
19. Bassetti CL, Dauvilliers Y: **Idiopathic hypersomnia.** In *Principles and Practice of Sleep Medicine*. 5th edition. Edited by Kryger MH, Roth T, Dement WC ED. Elsevier Saunders; 2011:969–989.
20. Ohayon MM, Reynolds CF, Dauvilliers Y: **The link between excessive quantity of sleep and deteriorated quality of wakefulness – implications for the DSM-5.** *Ann Neurol*. in press.
21. Buysse DJ, Ancoli-Israel S, Edinger JD, Lichstein KL, Morin CM: **Recommendations for a standard research assessment of insomnia.** *Sleep* 2006, **29**:1155–1173.
22. Martin JL, Hakim AD: **Wrist actigraphy.** *Chest* 2011, **139**:1514–1527.
23. Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B, Brown T, Chesson A Jr, Coleman J, Lee-Chiong T, Pancer J, Swick TJ, Standards of Practice Committee, American Academy of Sleep Medicine: **Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007.** *Sleep* 2007, **30**:519–529.
24. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP: **The role of actigraphy in the study of sleep and circadian rhythms.** *Sleep* 2003, **26**:342–392.
25. Billiard M: **Idiopathic hypersomnia.** *Neurol Clin* 1996, **14**:573–582.
26. Vernet C, Arnulf I: **Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients.** *Sleep* 2009, **32**:753–759.
27. WHO: *The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research*. Geneva, Switzerland: World Health Organization; 1993.
28. Reynolds C, Redline S, DSM-V Sleep-Wake Disorders Workgroup and Advisors: **The DSM-V sleep-wake disorders nosology: an update and an invitation to the sleep community.** *Sleep* 2010, **33**:10–11.
29. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA: **Seasonal affective disorder, A description of the syndrome and preliminary findings with light therapy.** *Arch Gen Psychiatry* 1984, **41**:72–80.
30. First MB, Spitzer RL, Gibbon M, William JBW: *Structured Clinical Interview for DSM-IV (SCID) Axis I Disorders*. Washington (DC): American Psychiatric Press; 1997.
31. Beck AT, Steer RA, Brown GK: *Inventaire de dépression de Beck*. Paris, France: Editions du Centre de Psychologie Appliquée; 1998.
32. Hamilton M: **A rating scale for depression.** *J Neurol Neurosurg Psychiatry* 1960, **23**:56–62.
33. Montgomery SA, Asberg M: **A new depression scale designed to be sensitive to change.** *Br J Psychiatry* 1979, **134**:382–389.
34. Zung WKK: **A self-rating depression scale.** *Arch Gen Psychiatry* 1965, **12**:63–70.
35. Zigmond AS, Snaith RP: **The hospital anxiety and depression scale.** *Acta Psychiatr Scand* 1983, **67**:361–370.
36. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH: **The Inventory of Depressive Symptomatology (IDS): psychometric properties.** *Psychol Med* 1996, **26**:477–486.
37. Buckley: **A psychometrical evaluation of the BDI-II in treatment-seeking substance abusers.** *J Subst Abuse Treat* 2001, **20**:197–204.
38. Akiskal HS, Benazzi F: **Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?** *J Affect Disord* 2005, **84**:209–217.
39. Williamson DE, Birmaher B, Brent DA, Balach L, Dahl RE, Ryan ND: **Atypical symptoms of depression in a sample of depressed child and adolescent outpatients.** *J Am Acad Child Adolesc Psychiatry* 2000, **39**:1253–1259.
40. Sørensen MJ, Nissen JB, Mors O, Thomsen PH: **Age and gender differences in depressive symptomatology and comorbidity: an incident sample of psychiatrically admitted children.** *J Affect Disord* 2005, **84**:85–91.
41. Roberts RE, Shema SJ, Kaplan GA, Strawbridge WJ: **Sleep complaints and depression in an aging cohort: a prospective perspective.** *Am J Psychiatry* 2000, **157**:81–88.
42. Breslau N, Roth T, Rosenthal L, Andreski P: **Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.** *Biol Psychiatry* 1996, **39**:411–418.
43. Plante DT, Landsness EC, Peterson MJ, Goldstein MR, Riedner BA, Wanger T, Guokas JJ, Tononi G, Benca RM: **Sex-related differences in sleep slow wave activity in major depressive disorder: a high-density EEG investigation.** *BMC Psychiatry* 2012, **12**:146.
44. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N: **Differences between minimally depressed patients who do and do not consider themselves to be in remission.** *J Clin Psychiatry* 2005, **66**:1134–1138.
45. Worthington J, Fava M, Davidson K, Alpert J, Nierenberg AA, Rosenbaum JF: **Patterns of improvement in depressive symptoms with fluoxetine treatment.** *Psychopharmacol Bull* 1995, **31**:223–226.
46. Mathers CD, Loncar D: **Projections of global mortality and burden of disease from 2002 to 2030.** *PLoS Med* 2006, **3**:e442.
47. Kaplan KA, Gruber J, Eidelman P, Talbot LS, Harvey AG: **Hypersomnia in inter-episode bipolar disorder: does it have prognostic significance?** *J Affect Disord* 2011, **132**:438–444.
48. Avery DH, Khan A, Dager SR, Cohen S, Cox GB, Dunner DL: **Morning or evening bright light treatment of winter depression? The significance of hypersomnia.** *Biol Psychiatry* 1991, **29**:117–126.
49. Allen JM, Lam RW, Remick RA, Sadovnick AD: **Depressive symptoms and family history in seasonal and nonseasonal mood disorders.** *Am J Psychiatry* 1993, **150**:443–448.
50. Terman M, Amira L, Terman JS, Ross DC: **Predictors of response and nonresponse to light treatment for winter depression.** *Am J Psychiatr*. 1996, **153**:1423–1429.
51. Tam EM, Lam RW, Robertson HA, Stewart JN, Yatham LN, Zis AP: **Atypical depressive symptoms in seasonal and non-seasonal mood disorders.** *J Affect Disord* 1997, **44**:39–44.
52. Winkler D, Willeit M, Praschak-Rieder N, Lucht MJ, Hilger E, Konstantinidis A, Stastny J, Thierry N, Pjrek E, Neumeister A, Möller HJ, Kasper S: **Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample.** *Eur Arch Psychiatry Clin Neurosci* 2002, **252**:54–62.
53. Shapiro CM, Devins GM, Feldman B, Levitt AJ: **Is hypersomnolence a feature of seasonal affective disorder?** *J Psychosom Res* 1994, **38**:49–54.
54. Nofzinger EA, Thase ME, Reynolds CF 3rd, Himmelhoch JM, Mallinger A, Houck P, Kupfer DJ: **Hypersomnia in bipolar depression: a comparison**

- with narcolepsy using the multiple sleep latency test. *Am J Psychiatry* 1991, **148**:1177–1781.
55. Billiard M, Partinen M, Roth T, Shapiro C: **Sleep and psychiatric disorders.** *J Psychosom Res* 1994, **38**:1–2.
56. Dolenc L, Besset A, Billiard M: **Hypersomnia in association with dysthymia in comparison with idiopathic hypersomnia and normal controls.** *Pflugers Arch* 1996, **431**:R303–R304.
57. Vgontzas AN, Bixler EO, Kales A, Criley C, Vela-Bueno A: **Differences in nocturnal and daytime sleep between primary and psychiatric hypersomnia: diagnostic and treatment implications.** *Psychosom Med* 2000, **62**:220–226.
58. Jennum P, Kjellberg J: **The socio-economical burden of hypersomnia.** *Acta Neurol Scand* 2010, **121**:265–270.
59. Dauvilliers Y, Arnulf I, Mignot E: **Narcolepsy with cataplexy.** *Lancet* 2007, **369**:499–511.
60. Dauvilliers Y, Montplaisir J, Molinari N, Carlander B, Ondze B, Besset A, Billiard M: **Age at onset of narcolepsy in two large populations of patients in France and Quebec.** *Neurology* 2001, **57**:2029–2033.
61. Fortuyn HA, Mulders PC, Renier WO, Buitelaar JK, Overeem S: **Narcolepsy and psychiatry: an evolving association of increasing interest.** *Sleep Med* 2011, **12**:714–719.
62. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E: **A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.** *Nat Med* 2000, **6**:991–997.
63. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM: **Reduced number of hypocretin neurons in human narcolepsy.** *Neuron* 2000, **27**:469–474.
64. Dauvilliers Y, Baumann CR, Carlander B, Bischof M, Blatter T, Lecendreux M, Maly F, Besset A, Touchon J, Billiard M, Tafti M, Bassetti CL: **CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions.** *J Neurol Neurosurg Psychiatry* 2003, **74**:1667–1673.
65. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S: **The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.** *Arch Neurol* 2002, **59**:1553–1562.
66. Nishino S, Okuro M, Kotorii N, Ane-gawa E, Ishimaru Y, Matsumura M, Kanbayashi T: **Hypocretin/orexin and narcolepsy: new basic and clinical insights.** *Acta Physiol (Oxf)* 2010, **198**:209–222.
67. Oka Y, Inoue Y, Kanbayashi T, Kuroda K, Miyamoto M, Miyamoto T, Ikeda A, Shimizu T, Hishikawa Y, Shibasaki H: **Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.** *Sleep* 2006, **29**:1439–1443.
68. Sakurai T: **The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness.** *Nat Rev Neurosci* 2007, **8**:171–181.
69. Roy A: **Psychiatric aspects of narcolepsy.** *Br J Psychiatry* 1976, **128**:562–565.
70. Kales A, Soldatos CR, Bixler EO, Caldwell A, Cadieux RJ, Verrechio JM, Kales JD: **Narcolepsy-cataplexy, II. Psychosocial consequences and associated psychopathology.** *Arch Neurol* 1982, **39**:169–171.
71. Krishnan RR, Volow MR, Miller PP, Carwile ST: **Narcolepsy: preliminary retrospective study of psychiatric and psychosocial aspects.** *Am J Psychiatry* 1984, **141**:428–431.
72. Mosko S, Zetin M, Glen S, Garber D, DeAntonio M, Sassin J, McAnich J, Warren S: **Self-reported depressive symptomatology, mood ratings, and treatment outcome in sleep disorders patients.** *J Clin Psychol* 1989, **45**:51–60.
73. Vourdas A, Shneerson JM, Gregory CA, Smith IE, King MA, Morrish E, McKenna PJ: **Narcolepsy and psychopathology: is there an association?** *Sleep Med* 2002, **3**:353–360.
74. Fortuyn HA, Lappenschaar MA, Furer JW, Hodi-amont PP, Rijnders CA, Renier WO, Buitelaar JK, Overeem S: **Anxiety and mood disorders in narcolepsy: a case-control study.** *Gen Hosp Psychiatry* 2010, **32**:49–56.
75. Vandeputte M, de Weerd A: **Sleep disorders and depressive feelings: a global survey with the Beck depression scale.** *Sleep Med* 2003, **4**:343–345.
76. Dauvilliers Y, Paquereau J, Bastuji H, Drouot X, Weil JS, Viot-Blanc V: **Psychological health in central hypersomnias: the French Harmony study.** *J Neurol Neurosurg Psychiatry* 2009, **80**:636–641.
77. Bayard S, Abril B, Yu H, Scholz S, Carlander B, Dauvilliers Y: **Decision making in narcolepsy with cataplexy.** *Sleep* 2011, **34**:99–104.
78. Bayard S, Croisier Langenier M, Cochen De Cock V, Scholz S, Dauvilliers Y: **Executive control of attention in narcolepsy.** *PLoS One* 2012, **7**:e33525.
79. Szklo-Coxe M, Young T, Finn L, Mignot E: **Depression: relationships to sleep paralysis and other sleep disturbances in a community sample.** *J Sleep Res* 2007, **16**:297–312.
80. Vignatelli L, D'Alessandro R, Mosconi P, Ferini-Strambi L, Guidolin L, De Vincentiis A, Plazzi G, GINSEN (Gruppo Italiano Narcolessia-Studio Epidemiologico Nazionale): **Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey.** *Sleep Med* 2004, **5**:467–475.
81. Vignatelli L, Plazzi G, Peschchera F, Delaj L, D'Alessandro R: **A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy.** *Sleep Med* 2011, **12**:19–23.
82. Dodel R, Peter H, Spottke A, Noelker C, Althaus A, Siebert U, Walbert T, Kesper K, Becker HF, Mayer G: **Health-related quality of life in patients with narcolepsy.** *Sleep Med* 2007, **8**:733–741.
83. Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, Nestler EJ, Elmquist JK, Lutter M: **Hcrtr1 and 2 signaling differentially regulates depression-like behaviors.** *Behav Brain Res* 2011, **222**:289–294.
84. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, Mignot E: **Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.** *Biol Psychiatry* 2003, **54**:96–104.
85. Brundin L, Björkqvist M, Petersén A, Träskman-Bendz L: **Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder.** *Eur Neuropsychopharmacol* 2007, **17**:573–579.
86. Schmidt FM, Brügel M, Kratzsch J, Strauss M, Sander C, Baum P, Thiery J, Hegerl U, Schönknecht P: **Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls.** *Neurosci Lett* 2010, **483**:20–22.
87. Schmidt FM, Arendt E, Steinmetzer A, Bruegel M, Kratzsch J, Strauss M, Baum P, Hegerl U, Schönknecht P: **CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls.** *Psychiatry Res* 2011, **190**:240–243.
88. Billiard M, Dauvilliers Y: **Idiopathic hypersomnia.** *Sleep Med Rev* 2001, **5**:349–358.
89. Bassetti C, Aldrich MS: **Idiopathic hypersomnia. A series of 42 patients.** *Brain* 1997, **120**:1423–1435.
90. Roth B, Nevsimalova S: **Depression in narcolepsy and hypersomnia.** *Schweiz Arch Neurol Neurochir Psychiatr* 1975, **116**:291–300.
91. Komada Y, Inoue Y, Hayashida K, Nakajima T, Honda M, Takahashi K: **Clinical significance and correlates of behaviorally induced insufficient sleep syndrome.** *Sleep Med* 2008, **9**:851–856.
92. Pallesen S, Nordhus IH, Omvik S, Sivertsen B, Tell GS, Bjorvatn B: **Prevalence and risk factors of subjective sleepiness in the general adult population.** *Sleep* 2007, **30**:619–624.
93. Pallesen S, Saxvig IW, Molde H, Sørensen E, Wilhelmsen-Langeland A, Bjorvatn B: **Brief report: behaviorally induced insufficient sleep syndrome in older adolescents: prevalence and correlates.** *J Adolesc* 2011, **34**:391–395.

doi:10.1186/1741-7015-11-78

Cite this article as: Dauvilliers et al: Hypersomnia and depressive symptoms: methodological and clinical aspects. *BMC Medicine* 2013 11:78.